Analgesics Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Analgesics Market, By Drug Class

7.1. Analgesics Market, by Drug Class, 2024-2034

7.1.1. Opioids

7.1.1.1. Market Revenue and Forecast (2021-2034)

7.1.2. NSAIDs

7.1.2.1. Market Revenue and Forecast (2021-2034)

7.1.3. Local Anesthetics

7.1.3.1. Market Revenue and Forecast (2021-2034)

7.1.4. Acetaminophen

7.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 8. Global Analgesics Market, By Indication

8.1. Analgesics Market, by Indication, 2024-2034

8.1.1. Surgical Pain

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Cancer Pain

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Neuropathic Pain

8.1.3.1. Market Revenue and Forecast (2021-2034)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Analgesics Market, By Type

9.1. Analgesics Market, by Type, 2024-2034

9.1.1. Prescription

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. OTC

9.1.2.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Analgesics Market, By Pain Type

10.1. Analgesics Market, by Pain Type, 2024-2034

10.1.1. Musculoskeletal Pain

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Surgical and Trauma Pain

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Cancer Pain

10.1.3.1. Market Revenue and Forecast (2021-2034)

10.1.4. Neuropathic Pain

10.1.4.1. Market Revenue and Forecast (2021-2034)

10.1.5. Migraine

10.1.5.1. Market Revenue and Forecast (2021-2034)

10.1.6. Obstetrical Pain

10.1.6.1. Market Revenue and Forecast (2021-2034)

10.1.7. Fibromyalgia

10.1.7.1. Market Revenue and Forecast (2021-2034)

10.1.8. Pain due to Burns

10.1.8.1. Market Revenue and Forecast (2021-2034)

10.1.9. Dental/Facial Pain

10.1.9.1. Market Revenue and Forecast (2021-2034)

10.1.10. Paediatric Pain

10.1.10.1. Market Revenue and Forecast (2021-2034)

10.1.11. Others

10.1.11.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Analgesics Market, By Application

11.1. Analgesics Market, by Application, 2024-2034

11.1.1. Internal Analgesics

11.1.1.1. Market Revenue and Forecast (2021-2034)

11.1.2. External Analgesics

11.1.2.1. Market Revenue and Forecast (2021-2034)

Chapter 12. Global Analgesics Market, By Route of Administration

12.1. Analgesics Market, by Route of Administration, 2024-2034

12.1.1. Oral

12.1.1.1. Market Revenue and Forecast (2021-2034)

12.1.2. Oral

12.1.2.1. Market Revenue and Forecast (2021-2034)

12.1.3. Transdermal

12.1.3.1. Market Revenue and Forecast (2021-2034)

12.1.4. Others

12.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 13. Global Analgesics Market, By Distribution Channel

13.1. Analgesics Market, by Distribution Channel, 2024-2034

13.1.1. Hospital pharmacies

13.1.1.1. Market Revenue and Forecast (2021-2034)

13.1.2. Retail pharmacies

13.1.2.1. Market Revenue and Forecast (2021-2034)

13.1.3. Drug Stores

13.1.3.1. Market Revenue and Forecast (2021-2034)

13.1.4. Online pharmacies

13.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 14. Global Analgesics Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.1.2. Market Revenue and Forecast, by Indication (2021-2034)

14.1.3. Market Revenue and Forecast, by Type (2021-2034)

14.1.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.1.5. Market Revenue and Forecast, by Application (2021-2034)

14.1.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.1.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.1.8. U.S.

14.1.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.1.8.2. Market Revenue and Forecast, by Indication (2021-2034)

14.1.8.3. Market Revenue and Forecast, by Type (2021-2034)

14.1.8.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.1.8.5. Market Revenue and Forecast, by Application (2021-2034)

14.1.8.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.1.8.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.1.9.2. Market Revenue and Forecast, by Indication (2021-2034)

14.1.9.3. Market Revenue and Forecast, by Type (2021-2034)

14.1.9.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.1.9.5. Market Revenue and Forecast, by Application (2021-2034)

14.1.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.1.9.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.2. Europe

14.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.2.2. Market Revenue and Forecast, by Indication (2021-2034)

14.2.3. Market Revenue and Forecast, by Type (2021-2034)

14.2.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.2.5. Market Revenue and Forecast, by Application (2021-2034)

14.2.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.2.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.2.8.2. Market Revenue and Forecast, by Indication (2021-2034)

14.2.8.3. Market Revenue and Forecast, by Type (2021-2034)

14.2.8.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.2.8.5. Market Revenue and Forecast, by Application (2021-2034)

14.2.8.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.2.8.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.2.9. Germany

14.2.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.2.9.2. Market Revenue and Forecast, by Indication (2021-2034)

14.2.9.3. Market Revenue and Forecast, by Type (2021-2034)

14.2.9.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.2.9.5. Market Revenue and Forecast, by Application (2021-2034)

14.2.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.2.9.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.2.10. France

14.2.10.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.2.10.2. Market Revenue and Forecast, by Indication (2021-2034)

14.2.10.3. Market Revenue and Forecast, by Type (2021-2034)

14.2.10.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.2.10.5. Market Revenue and Forecast, by Application (2021-2034)

14.2.10.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.2.10.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.2.11. Rest of Europe

14.2.11.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.2.11.2. Market Revenue and Forecast, by Indication (2021-2034)

14.2.11.3. Market Revenue and Forecast, by Type (2021-2034)

14.2.11.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.2.11.5. Market Revenue and Forecast, by Application (2021-2034)

14.2.11.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.2.11.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.3.2. Market Revenue and Forecast, by Indication (2021-2034)

14.3.3. Market Revenue and Forecast, by Type (2021-2034)

14.3.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.3.5. Market Revenue and Forecast, by Application (2021-2034)

14.3.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.3.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.3.8. India

14.3.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.3.8.2. Market Revenue and Forecast, by Indication (2021-2034)

14.3.8.3. Market Revenue and Forecast, by Type (2021-2034)

14.3.8.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.3.8.5. Market Revenue and Forecast, by Application (2021-2034)

14.3.8.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.3.8.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.3.9. China

14.3.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.3.9.2. Market Revenue and Forecast, by Indication (2021-2034)

14.3.9.3. Market Revenue and Forecast, by Type (2021-2034)

14.3.9.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.3.9.5. Market Revenue and Forecast, by Application (2021-2034)

14.3.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.3.9.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.3.10. Japan

14.3.10.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.3.10.2. Market Revenue and Forecast, by Indication (2021-2034)

14.3.10.3. Market Revenue and Forecast, by Type (2021-2034)

14.3.10.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.3.10.5. Market Revenue and Forecast, by Application (2021-2034)

14.3.10.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.3.10.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.3.11. Rest of APAC

14.3.11.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.3.11.2. Market Revenue and Forecast, by Indication (2021-2034)

14.3.11.3. Market Revenue and Forecast, by Type (2021-2034)

14.3.11.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.3.11.5. Market Revenue and Forecast, by Application (2021-2034)

14.3.11.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.3.11.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.4.2. Market Revenue and Forecast, by Indication (2021-2034)

14.4.3. Market Revenue and Forecast, by Type (2021-2034)

14.4.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.4.5. Market Revenue and Forecast, by Application (2021-2034)

14.4.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.4.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.4.8. GCC

14.4.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.4.8.2. Market Revenue and Forecast, by Indication (2021-2034)

14.4.8.3. Market Revenue and Forecast, by Type (2021-2034)

14.4.8.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.4.8.5. Market Revenue and Forecast, by Application (2021-2034)

14.4.8.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.4.8.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.4.9. North Africa

14.4.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.4.9.2. Market Revenue and Forecast, by Indication (2021-2034)

14.4.9.3. Market Revenue and Forecast, by Type (2021-2034)

14.4.9.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.4.9.5. Market Revenue and Forecast, by Application (2021-2034)

14.4.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.4.9.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.4.10. South Africa

14.4.10.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.4.10.2. Market Revenue and Forecast, by Indication (2021-2034)

14.4.10.3. Market Revenue and Forecast, by Type (2021-2034)

14.4.10.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.4.10.5. Market Revenue and Forecast, by Application (2021-2034)

14.4.10.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.4.10.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.4.11. Rest of MEA

14.4.11.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.4.11.2. Market Revenue and Forecast, by Indication (2021-2034)

14.4.11.3. Market Revenue and Forecast, by Type (2021-2034)

14.4.11.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.4.11.5. Market Revenue and Forecast, by Application (2021-2034)

14.4.11.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.4.11.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.5.2. Market Revenue and Forecast, by Indication (2021-2034)

14.5.3. Market Revenue and Forecast, by Type (2021-2034)

14.5.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.5.5. Market Revenue and Forecast, by Application (2021-2034)

14.5.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.5.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.5.8. Brazil

14.5.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.5.8.2. Market Revenue and Forecast, by Indication (2021-2034)

14.5.8.3. Market Revenue and Forecast, by Type (2021-2034)

14.5.8.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.5.8.5. Market Revenue and Forecast, by Application (2021-2034)

14.5.8.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.5.8.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)

14.5.9.2. Market Revenue and Forecast, by Indication (2021-2034)

14.5.9.3. Market Revenue and Forecast, by Type (2021-2034)

14.5.9.4. Market Revenue and Forecast, by Pain Type (2021-2034)

14.5.9.5. Market Revenue and Forecast, by Application (2021-2034)

14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2021-2034)

14.5.9.7. Market Revenue and Forecast, by Route of Administration (2021-2034)

Chapter 15. Company Profiles

15.1. Abbott

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Pfizer Inc.

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Eli Lilly & Company

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Endo International plc

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. F. Hoffmann-La Roche AG

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Bausch Health Companies Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Merck & Co. Inc.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. AbbVie Inc.

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Novartis AG

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Johnson & Johnson Private Limited

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms